An Open-Label, Multicenter Phase 4 Study To Assess Disease Activity And Biomarkers Of Neuronal Damage In Minority Patients With Relapsing Multiple Sclerosis Receiving Treatment With Ocrelizumab
Posted Date: Mar 19, 2021
- Investigator: Lawrence Goldstick
- Specialties: Multiple Sclerosis, Neurology
- Type of Study: Drug
The primary objective of this study is to assess disease activity during treatment with ocrelizumab in minorities represented by Black/African Americans with RMS and Hispanic/Latinos with RMS.
Participant Must Be Between 18-65 And Have Been Diagnosed With Relapsing Multiple Sclerosis (Rms). Participant Must Identify As Black/African- American Or Hispanic/Latino. Patient Must Have Been On A Maximum Of 2 Prior Ms Medications.
Relapsing Multiple Sclerosis, Neurology, Ocrelizumab
For More Information: